NDAORALCAPSULE
Approved
Sep 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBRAX is a fixed-dose oral combination of chlordiazepoxide hydrochloride (a benzodiazepine) and clidinium bromide (an anticholinergic agent) approved in 1966 for gastrointestinal and anxiety indications. The benzodiazepine component provides anxiolytic and sedative effects while the anticholinergic component reduces gastrointestinal motility and secretion. It represents a legacy polypharmacy approach to treating functional GI disorders with concurrent anxiety.
$3MPart D
LOE ApproachingDeclining
The product is in late-stage market decline with minimal prescription volume, suggesting limited headcount growth and focus on cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
Started May 2011
21 enrolled
Parkinson's Disease
Career Relevance
LIBRAX generates virtually no career opportunities because it is a legacy product with minimal revenue, declining prescriptions, and no clinical or commercial expansion pipeline. Positions associated with this product are primarily administrative, compliance, or supply-chain oriented rather than commercial or strategic growth roles.
Company
Worked on LIBRAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.